- Home
- XNCR vs IMNM Comparison
XNCR vs IMNM Comparison
Compare XNCR & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- IMNM
- Stock Information
- Founded
- XNCR 1997
- IMNM 2006
- Country
- XNCR United States
- IMNM United States
- Employees
- XNCR N/A
- IMNM N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- XNCR Health Care
- IMNM Health Care
- Exchange
- XNCR Nasdaq
- IMNM Nasdaq
- Market Cap
- XNCR 1.1B
- IMNM 1.2B
- IPO Year
- XNCR 2013
- IMNM 2020
- Fundamental
- Price
- XNCR $13.86
- IMNM $17.17
- Analyst Decision
- XNCR Buy
- IMNM Strong Buy
- Analyst Count
- XNCR 11
- IMNM 9
- Target Price
- XNCR $24.20
- IMNM $24.89
- AVG Volume (30 Days)
- XNCR 1.5M
- IMNM 1.2M
- Earning Date
- XNCR 11-06-2025
- IMNM 11-17-2025
- Dividend Yield
- XNCR N/A
- IMNM N/A
- EPS Growth
- XNCR N/A
- IMNM N/A
- EPS
- XNCR N/A
- IMNM N/A
- Revenue
- XNCR $146,929,000.00
- IMNM $12,589,000.00
- Revenue This Year
- XNCR $22.09
- IMNM N/A
- Revenue Next Year
- XNCR N/A
- IMNM $85.68
- P/E Ratio
- XNCR N/A
- IMNM N/A
- Revenue Growth
- XNCR N/A
- IMNM 16.74
- 52 Week Low
- XNCR $6.92
- IMNM $5.15
- 52 Week High
- XNCR $27.24
- IMNM $17.87
- Technical
- Relative Strength Index (RSI)
- XNCR 55.63
- IMNM 66.47
- Support Level
- XNCR $12.17
- IMNM $15.44
- Resistance Level
- XNCR $15.50
- IMNM $17.21
- Average True Range (ATR)
- XNCR 1.15
- IMNM 1.22
- MACD
- XNCR -0.12
- IMNM -0.10
- Stochastic Oscillator
- XNCR 49.86
- IMNM 78.53
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.